Scientists identify new target for developing novel drugs against several types of cancer

The Bcl-2 protein family comprises anti- and proapoptotic members, i.e. they protect the cell from death or favour it.

In the study, they have demonstrated and characterized the interaction between Mcl-1 and Bok, two important proteins in this family, which, according to Ismael Mingarro, "control the permeabilisation of the mitochondrial outer membrane, a crucial step in modulating the apoptotic processes of cell death".

Our results suggest that the interaction between Mcl-1 and Bok is a good target for developing new drugs to treat several types of cancer such as malignant melanomas or pulmonary adenocarcinomas",

Ismael Mingarro, Professor and Predoctoral Researcher, University Institute of Biotechnology and Biomedicine, UV Gerard Duart

As the article explains, these cancers have elevated levels of expression of the Mcl-1 protein and/or mutations in their transmembrane segment that correlate with a bad prognosis and low response to current treatments.

Professor Mingarro states that the interaction between these two proteins is specific and occurs in the membrane environment through their hydrophobic (transmembrane) regions of the carboxy-terminal ends of both proteins, unlike among most proteins in the Bcl-2 family that interact with the soluble regions of proteins.

Journal reference:

Lucendo, E., et al. (2020) Mcl-1 and Bok transmembrane domains: Unexpected players in the modulation of apoptosis. PNAS.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Retroviruses invading the koala germline contribute to high cancer rates